REBEC

Public trial

Effects of water-based therapy on balance, mobility, motor function and behavior in children with Autism: a randomized clinical trial

Date of registration: 04/08/2026 ^(mm/dd/yyyy)
Last approval date : 04/08/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Self-Massage for Pain Relief in Parkinson's Patients: Initial Study with Cost Analysis

Date of registration: 04/08/2026 ^(mm/dd/yyyy)
Last approval date : 04/08/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Beach Tennis versus Combined Training on 24-hour Blood Pressure

Date of registration: 04/08/2026 ^(mm/dd/yyyy)
Last approval date : 04/08/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Treatment to reduce tooth sensitivity in children with enamel defects and its impact on quality of life

Date of registration: 04/08/2026 ^(mm/dd/yyyy)
Last approval date : 04/08/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Influence of the time of day and indoor luminosity on the responses of the heart and vessels to the execution of a bou of exercise on the cycle ergometer

Date of registration: 04/08/2026 ^(mm/dd/yyyy)
Last approval date : 04/08/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

How Pilates can help with blood pressure and circulation in individuals with high blood pressure

Date of registration: 04/07/2026 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of Low-Intensity Laser with Methylene Blue to treat Nipple Cracks during Breastfeeding

Date of registration: 04/07/2026 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Nitrate-rich food intake in elderly individuals

Date of registration: 09/26/2022 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 3

Study type:

Interventional

How the use of dentures may influence taste and the perception of flavors in older adults

Date of registration: 04/07/2026 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Comparison of the effects of antibiotic use on pain and infection symptoms after lower third molar removal surgery: a randomized, triple-blind clinical trial

Date of registration: 04/07/2026 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Passagem study: lifestyle, sleep, health, nutrition, and bullying - monitoring in youth from Passagem, Rio Grande do Norte, Brazil

Date of registration: 04/07/2026 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Observational

The Effect of Manual Therapy on Female Sexual Pain: A Multicenter, Randomized, Controlled, Blinded Clinical Trial

Date of registration: 04/07/2026 ^(mm/dd/yyyy)
Last approval date : 04/07/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The Effects of Pilates on Menopausal Women on Urine Loss, Heart Health and Sleep Quality

Date of registration: 11/04/2024 ^(mm/dd/yyyy)
Last approval date : 04/06/2026 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Evaluation of early Methylene Blue in the microcirculation of patients with Generalized Infections: a feasibility randomized controlled trial

Date of registration: 12/01/2025 ^(mm/dd/yyyy)
Last approval date : 04/06/2026 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Program with digital support and personalized guidance to improve lifestyle habits of low-income older women

Date of registration: 04/06/2026 ^(mm/dd/yyyy)
Last approval date : 04/06/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical effects of an anti-inflammatory diet in Type 2 Diabetes

Date of registration: 04/06/2026 ^(mm/dd/yyyy)
Last approval date : 04/06/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study on the brain health of the population of Porto Alegre

Date of registration: 04/06/2026 ^(mm/dd/yyyy)
Last approval date : 04/06/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Ayahuasca in the treatment of alcohol addiction

Date of registration: 04/06/2026 ^(mm/dd/yyyy)
Last approval date : 04/06/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the use of toothpaste with Brazilian red propolis to relieve tooth sensitivity.

Date of registration: 04/05/2026 ^(mm/dd/yyyy)
Last approval date : 04/05/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of intravenous iron to treat anemia before gynecological surgery

Date of registration: 04/02/2026 ^(mm/dd/yyyy)
Last approval date : 04/02/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

04/12/2026

How Big Pharma’s China Trials Are Escaping Scrutiny

04/12/2026 | Savannah Billman | The Wire China

https://www.thewirechina.com/2026/04/12/how-big-pharmas-china-trials-are-escaping-scrutiny/

U.S. supply chains with connections to Xinjiang and the Chinese military are heavily regulated — just not for pharmaceuticals.

U.S. sanctions on Chinese companies operating in Xinjiang or with the Chinese military have reshaped supply chains from agriculture to technology. It’s a different story for the pharmaceutical industry.

For multinational drugmakers with R&D investments and human trials running at Chinese hospitals, there is no regulation prohibiting drug development or clinical testing in a region otherwise subject to a range of existing U.S. sanctions and restrictions.

Data put together by The Wire China and WireScreen from ClinicalTrials.gov, a medical trial database maintained by the U.S. National Library of Medicine, shows that multinational companies have for years actively been sponsoring medical trials taking place in Xinjiang and at People’s Liberation Army-affiliated sites.

The true scope of this testing is difficult to measure. ClinicalTrials.gov requires registered trials to conform to regulations from regional authorities, but some trials only list the city where the test is held, not the hospital. PLA hospitals also do not always openly identify their military affiliation. China has 165 PLA hospitals across each of its provinces, according to WireScreen data.

For multinational pharmaceutical firms, these sites may just be one of dozens of worldwide locations testing a drug. Testing at multiple locations allows companies to collect data on how medicine impacts a variety of people under unique conditions. The results are used by companies seeking approval from regulatory agencies…

04/12/2026

Brazilian Government Approves New Framework for Cancer Prevention and Control in the SUS

04/10/2026 | Rafaelle Pereira | Ministry of Health

https://www.gov.br/saude/pt-br/assuntos/noticias/2026/abril/governo-do-brasil-sanciona-novo-marco-para-prevencao-e-controle-do-cancer-no-sus

Bill signed in São Paulo strengthens the Health Economic-Industrial Complex and promotes national sovereignty in the development of technologies and diagnostic tests

On Friday (10), the Unified Health System (SUS) achieved a new milestone for the National Policy on Cancer Prevention and Control. Signed into law by President Luiz Inácio Lula da Silva and Minister Alexandre Padilha in São Paulo, Bill No. 125/2025 aims to modernize the system and ensure access to innovations such as advanced therapies, vaccines, and new diagnostic tests.

In practice, the new regulations expand the national capacity for development, research, production, distribution, and access to cancer vaccines, with a focus on universal access and equity within the SUS, through the promotion of research, domestic production, and international collaboration.

During the ceremony in São Paulo, on an inaugural visit to the Center for Teaching, Simulation, and Innovation (Cesin) at the Heart Institute (InCor), at the Hospital das Clínicas of the USP School of Medicine, the president highlighted the government’s commitment to the quality of public healthcare.

“My obsession is to prove that the Unified Health System can be equal to or better than any private institution. That is what we are doing: investing in cutting-edge technology to ensure that everyone has the right to the most modern treatment,” stated Luiz Inácio Lula da Silva.

The measure is part of the Brazilian government’s efforts, through the…

04/12/2026

PAHO Launches Clinical Trials Accelerator to Boost Research in the Americas

04/10/2026 | Roberta Santiago | Afya Portal

https://portal.afya.com.br/saude/opas-lanca-acelerador-de-ensaios-clinicos-para-impulsionar-pesquisa-nas-americas

Initiative aims to improve quality and strengthen the integration and impact of clinical studies in the Americas

The Pan American Health Organization has launched the Clinical Trials Accelerator, an initiative aimed at strengthening clinical research in the Americas. The goal is to improve the quality, expand the scale, and increase the impact of studies, especially in Latin America and the Caribbean, where trials still face challenges such as fragmentation and poor coordination.

Clinical trials are essential for the development of new therapies and for ensuring the safety and efficacy of health interventions. However, the lack of robust multicenter studies in the region hinders the production of consistent evidence to address public health issues.

Strategies for integration and efficiency
The Accelerator proposes the use of innovative tools to optimize all stages of research, from study design to data analysis, including solutions based on artificial intelligence. The initiative also aims to strengthen collaboration between countries and encourage the conduct of multicenter clinical trials.

Another key focus is the harmonization of regulatory processes. Standardizing contracts and administrative requirements should reduce delays, prevent duplication, and facilitate the conduct of research in a more agile manner, without compromising ethical and quality standards.

Regional Strengthening and the Legacy of the Pandemic
The creation of the Accelerator is based on lessons learned during the COVID-19 pandemic, which highlighted both the importance of coordinated research…

04/10/2026

Lidera Health Launches AI Platform for Medical Cannabis

04/09/2026 | Leandro Maia | Sechat

https://sechat.com.br/noticia/lidera-health-lanca-plataforma-de-ia-para-cannabis-medicinal-1

Healthtech presents a clinical system that promises to generate scientific evidence and enhance prescription safety in Brazil

Lidera Health, an American healthtech company with operations in Brazil, announced the launch of an artificial intelligence-based platform focused on medical cannabis. The goal is to fill a structural gap in the sector: the lack of clinical infrastructure capable of generating consistent scientific data from medical practice.

The system, classified as a Clinical Decision Support System (CDSS), integrates tools for clinical decision support, patient monitoring, and data structuring into formats compatible with scientific information. The solution serves various market stakeholders, including patient associations, pharmaceutical companies, clinics, and prescribing physicians.

For associations, the platform offers standardized patient monitoring with data collection at specific milestones—such as D7, D21, D30, D60, D90—as well as validated scales and adverse event tracking. The model aligns with recent regulatory requirements from Anvisa, particularly in the context of the regulatory sandbox, which requires the generation of evidence regarding quality, safety, and use.

For pharmaceutical companies, the system enables tracking of clinical outcomes by product and formulation, aligning with the use of real-world evidence already recognized by the regulatory agency. For physicians, the tool incorporates safety features such as drug interaction analysis, contraindications, clinical history, and continuous monitoring for up to 90 days after the prescription.

Data cited by the company indicates that up to 58% of patients discontinue cannabis…

04/09/2026

California bill threatens clinical trials

04/09/2026 | Bill Remak | Capitol Weekly - Opinion

https://capitolweekly.net/california-bill-threatens-clinical-trials/

California patients living with rare diseases and chronic conditions are enrolled into new clinical trials every day – not as a last resort, but as a pathway to better treatment and hope. Yet a bill moving through Sacramento could quietly put that progress at risk.

Assembly Bill (AB) 1776 would expand our state’s antitrust authority, increasing scrutiny over business practices and collaborations deemed “anticompetitive.” While well-intentioned, the bill overlooks a critical reality: medical innovation depends on collaboration. Researchers, manufacturers, and health systems must work together to develop and deliver new treatments – and clinical trials are where that collaboration comes to life for patients.

I was diagnosed with diabetes in 1994. Back then, managing the disease looked very different. It meant finger pricks throughout the day, strict routines, constant vigilance, and the ever-present fear of complications. Smart devices did not exist to monitor my glucose levels in real-time, and far fewer tools to help patients stay in control.

But today, I am part of a clinical trial using advanced glucose monitoring and insulin pump technology that communicate with each other and adjust in real time. It’s a meaningful step forward for patients – one that simply wouldn’t exist without the clinical research system that supports innovation.

Diabetes is one of the most pressing health challenges in our state. More than 3.5 million adults live with diabetes, and hundreds of thousands more are diagnosed each year. And, nearly one in four Californians over 65 live with the disease. For many of us, access to new treatments isn’t theoretical –…